Literature DB >> 36253578

Clinical features and pathogenicity assessment in patients with HTRA1-autosomal dominant disease.

Zheng He1, Lijun Wang1, Yichi Zhang1, Chunmao Yin1, Yanliang Niu2.   

Abstract

BACKGROUND: Heterozygous mutations in HTRA1 were recently found to cause autosomal dominant cerebral small vessel disease (CSVD), and it was named HTRA1-autosomal dominant disease (AD-HTRA1) in the consensus recommendations of the European Academy of Neurology. This study aimed to investigate the clinical features of a mutation in HTRA1 and the effect of HTRA1 mutation on white matter hyperintensity (WMH).
METHODS: A proband's brain magnetic resonance imaging (MRI) showed multiple lacunar infarctions and multiple WMH in the lateral ventricle, external capsule, frontal lobe and corpus callosum. The proband and family members were tested for CSVD-related genes by next-generation sequencing and the clinical data of the patients were collected. The published literature on AD-HTRA1 was collected, and the clinical characteristics and pathogenicity of the patients were summarized. Combined Annotation Dependent Depletion (CADD) is a tool for scoring the deleteriousness of single-nucleotide variants and insertion/deletion variants in the human genome. The relationship between the degree of WMH and the pathogenicity of the mutation was further analyzed. RESULT: It was found that the proband and her family members had a heterozygous missense mutation of c.854C > T (p.P285L) in the 4 exon of HTRA1 gene. A retrospective analysis of 5 families with c.854C > T mutation found that the patients had an early age of onset, cognitive impairment was more common, and alopecia and spondylosis could be combined at the same time. By univariate analysis, the severity of WMH was found to be significantly associated with the mutated CADD score (p < 0.05, Spearman's rho = 0.266).
CONCLUSION: The clinical manifestations of AD-HTRA1 with mutation site c.854C > T (p.P285L) are similar to CARASIL, and brain MRI are mainly moderate or severe WMH and lacunar infarction (LI). WMH are affected by mutation sites. Therefore, our pathogenicity score for mutations can predict the severity of WMH.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Autosomal dominant hereditary; Cerebral small vessel disease; HTRA1; Heterozygous mutation

Year:  2022        PMID: 36253578     DOI: 10.1007/s10072-022-06454-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  19 in total

1.  An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.

Authors:  Reiji Muto; Yasuo Sugita; Seiya Momosaki; Yuriko Ito; Yoshiyuki Wakugawa; Koichi Ohshima
Journal:  Neuropathology       Date:  2018-12-03       Impact factor: 1.906

2.  Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL.

Authors:  Hiroaki Nozaki; Taisuke Kato; Megumi Nihonmatsu; Yohei Saito; Ikuko Mizuta; Tomoko Noda; Ryoko Koike; Kazuhide Miyazaki; Muichi Kaito; Shoichi Ito; Masahiro Makino; Akihide Koyama; Atsushi Shiga; Masahiro Uemura; Yumi Sekine; Ayuka Murakami; Suzuko Moritani; Kenju Hara; Akio Yokoseki; Ryozo Kuwano; Naoto Endo; Takeshi Momotsu; Mari Yoshida; Masatoyo Nishizawa; Toshiki Mizuno; Osamu Onodera
Journal:  Neurology       Date:  2016-04-27       Impact factor: 9.910

3.  A new Italian family with HTRA1 mutation associated with autosomal-dominant variant of CARASIL: Are we pointing towards a disease spectrum?

Authors:  Silvia Favaretto; Monica Margoni; Leonardo Salviati; Luigi Pianese; Renzo Manara; Claudio Baracchini
Journal:  J Neurol Sci       Date:  2018-11-10       Impact factor: 3.181

4.  Heterozygous mutations of HTRA1 gene in patients with familial cerebral small vessel disease.

Authors:  Ilaria Di Donato; Silvia Bianchi; Gian Nicola Gallus; Alfonso Cerase; Ilaria Taglia; Francesca Pescini; Serena Nannucci; Carla Battisti; Domenico Inzitari; Leonardo Pantoni; Andrea Zini; Antonio Federico; Maria Teresa Dotti
Journal:  CNS Neurosci Ther       Date:  2017-08-06       Impact factor: 5.243

5.  Characteristic features and progression of abnormalities on MRI for CARASIL.

Authors:  Hiroaki Nozaki; Yumi Sekine; Toshio Fukutake; Yoshinori Nishimoto; Yutaka Shimoe; Akiko Shirata; Sohei Yanagawa; Mikio Hirayama; Masato Tamura; Masatoyo Nishizawa; Osamu Onodera
Journal:  Neurology       Date:  2015-07-02       Impact factor: 9.910

Review 6.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

7.  Intracranial arterial disease in CADASIL patients.

Authors:  Hyun Goo Kang; Jong S Kim
Journal:  J Neurol Sci       Date:  2015-11-17       Impact factor: 3.181

8.  Characterization of Heterozygous HTRA1 Mutations in Taiwanese Patients With Cerebral Small Vessel Disease.

Authors:  Yi-Chung Lee; Chih-Ping Chung; Nai-Chen Chao; Jong-Ling Fuh; Feng-Chi Chang; Bing-Wing Soong; Yi-Chu Liao
Journal:  Stroke       Date:  2018-06-12       Impact factor: 7.914

9.  A general framework for estimating the relative pathogenicity of human genetic variants.

Authors:  Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

10.  Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology.

Authors:  M Mancuso; M Arnold; A Bersano; A Burlina; H Chabriat; S Debette; C Enzinger; A Federico; A Filla; J Finsterer; D Hunt; S Lesnik Oberstein; E Tournier-Lasserve; H S Markus
Journal:  Eur J Neurol       Date:  2020-03-20       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.